Roche’s Ventana bid advances in court
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems is preliminarily enjoined from using certain anti-takeover provisions to avert Roche's $3 billion hostile bid for the Tucson-based cancer diagnostics firm under an Arizona federal district court decision Aug. 21. Swiss firm Roche launched its $75-per-share tender offer for Ventana June 27, and has extended the offer's expiration date from Aug. 23 to Sept. 20. The offer represents a 44% premium over Ventana's last stock closing price before the bid was announced, although the market price has since soared as high as $88. Ventana says it remains "steadfast" in its belief that Roche's bid is "wholly inadequate" (1"The Gray Sheet" July 2, 2007, p. 10)...
You may also be interested in...
Roche extends hostile bid for Ventana
Tissue-based cancer test firm Ventana continues to dismiss Roche's $3 billion unsolicited takeover offer as "grossly inadequate" after Roche extends its $75-per-share bid for a third time on Sept. 19 - this time until Nov. 1. The offer, launched in June, had been slated to expire Sept. 20. The 63,500 Ventana shares tendered to date represent just 0.19% of the company (1"The Gray Sheet" Aug. 27, 2007, In Brief)
Ventana snaps up Spring Bioscience
Tissue-based cancer diagnostics firm Ventana gains next generation rabbit monoclonal antibodies and other reagents to aid development of companion diagnostics for use with drugs through its $28.9 million cash purchase of Spring Bioscience. Announced Sept. 5, the deal for Fremont, Calif.-based Spring Bioscience will include up to an additional $11.7 million in milestone payments over the next two years - which could put its total value at $40.6 million. As a result of the purchase, Ventana increased its 2008 revenue forecast by $7 million - to a range of $377 million-$392 million. Ventana itself remains subject to a hostile takeover attempt by Roche that values the company at $3 billion (1"The Gray Sheet" Aug. 27, 2007, In Brief)...
Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says